WO2024094235A1 - Use of benzoxaborole-based compounds in therapy of diseases caused by amoebas of the naegleria genus - Google Patents
Use of benzoxaborole-based compounds in therapy of diseases caused by amoebas of the naegleria genus Download PDFInfo
- Publication number
- WO2024094235A1 WO2024094235A1 PCT/CZ2022/050116 CZ2022050116W WO2024094235A1 WO 2024094235 A1 WO2024094235 A1 WO 2024094235A1 CZ 2022050116 W CZ2022050116 W CZ 2022050116W WO 2024094235 A1 WO2024094235 A1 WO 2024094235A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ddd
- mmol
- activity
- fowleri
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 201000010099 disease Diseases 0.000 title claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 10
- XOQABDOICLHPIS-UHFFFAOYSA-N 1-hydroxy-2,1-benzoxaborole Chemical compound C1=CC=C2B(O)OCC2=C1 XOQABDOICLHPIS-UHFFFAOYSA-N 0.000 title claims description 5
- 241000224436 Naegleria Species 0.000 title abstract description 5
- 241000224421 Heterolobosea Species 0.000 title description 3
- 210000003001 amoeba Anatomy 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- 241000224438 Naegleria fowleri Species 0.000 claims abstract description 27
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims abstract description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 4
- 125000006239 protecting group Chemical group 0.000 claims abstract description 4
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- GDMJXXLVTYSBBE-UHFFFAOYSA-N 1,2-benzoxaborole Chemical group C1=CC=C2OB=CC2=C1 GDMJXXLVTYSBBE-UHFFFAOYSA-N 0.000 abstract description 12
- LVOQRLRNYRASSK-UHFFFAOYSA-N NCC1=CC=CC2=C1C(=BO2)OC1=CC=CC=C1 Chemical class NCC1=CC=CC2=C1C(=BO2)OC1=CC=CC=C1 LVOQRLRNYRASSK-UHFFFAOYSA-N 0.000 abstract description 3
- 206010014599 encephalitis Diseases 0.000 abstract description 3
- 201000011475 meningoencephalitis Diseases 0.000 abstract description 3
- 239000002207 metabolite Substances 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 229940002612 prodrug Drugs 0.000 abstract description 3
- 239000000651 prodrug Substances 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 241000224489 Amoeba Species 0.000 abstract description 2
- 125000003277 amino group Chemical group 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract description 2
- 238000010172 mouse model Methods 0.000 abstract description 2
- 244000045947 parasite Species 0.000 abstract description 2
- 230000004962 physiological condition Effects 0.000 abstract description 2
- 238000006467 substitution reaction Methods 0.000 abstract description 2
- 230000003071 parasitic effect Effects 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- -1 pyrazinoxy substituents Chemical group 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000842 anti-protozoal effect Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 229940036589 antiprotozoals Drugs 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910002666 PdCl2 Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- USZAGAREISWJDP-UHFFFAOYSA-N crisaborole Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 3
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- VVRHWLMUVDGIJJ-UHFFFAOYSA-N 1-hydroxy-3h-2,1-benzoxaborol-6-ol Chemical compound C1=C(O)C=C2B(O)OCC2=C1 VVRHWLMUVDGIJJ-UHFFFAOYSA-N 0.000 description 2
- FCWAFKJLDJXIIK-UHFFFAOYSA-N 2-bromo-4-[3-(1,3-dioxolan-2-yl)phenoxy]benzaldehyde Chemical compound C1=C(C=O)C(Br)=CC(OC=2C=C(C=CC=2)C2OCCO2)=C1 FCWAFKJLDJXIIK-UHFFFAOYSA-N 0.000 description 2
- ORZIHESPONWBAJ-UHFFFAOYSA-N 3-(1,3-dioxolan-2-yl)phenol Chemical compound OC1=CC=CC(C2OCCO2)=C1 ORZIHESPONWBAJ-UHFFFAOYSA-N 0.000 description 2
- MNSSDUXJBDJPMF-UHFFFAOYSA-N 4-[3-(1,3-dioxolan-2-yl)phenoxy]-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(OC=2C=C(C=CC=2)C2OCCO2)=CC=C1C=O MNSSDUXJBDJPMF-UHFFFAOYSA-N 0.000 description 2
- XTMDXEDJWWVAKJ-UHFFFAOYSA-N 4-[3-formyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]benzonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C(C(=C1)C=O)=CC=C1OC1=CC=C(C#N)C=C1 XTMDXEDJWWVAKJ-UHFFFAOYSA-N 0.000 description 2
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 2
- IEHZPKWXBVTRRG-UHFFFAOYSA-N C1=C(C=O)C(Br)=CC=C1OC1=CC=C(C#N)C=C1 Chemical compound C1=C(C=O)C(Br)=CC=C1OC1=CC=C(C#N)C=C1 IEHZPKWXBVTRRG-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910020889 NaBH3 Inorganic materials 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- USQKBFNKMYRGGS-UHFFFAOYSA-N [4-[(1-hydroxy-3h-2,1-benzoxaborol-5-yl)oxy]phenyl]methanamine Chemical compound C1=CC(CN)=CC=C1OC1=CC=C(B(O)OC2)C2=C1 USQKBFNKMYRGGS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- QVEMCOSZMZXRKN-UHFFFAOYSA-N 1,2-benzoxaborol-3-ylmethanamine Chemical class C1=CC=C2C(CN)=BOC2=C1 QVEMCOSZMZXRKN-UHFFFAOYSA-N 0.000 description 1
- OPZDXMCOWFPQPE-UHFFFAOYSA-N 2-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(Br)=C1 OPZDXMCOWFPQPE-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- GYENCAJAGYMHGR-UHFFFAOYSA-N [3-[(1-hydroxy-3h-2,1-benzoxaborol-5-yl)oxy]phenyl]methanamine Chemical compound NCC1=CC=CC(OC=2C=C3COB(O)C3=CC=2)=C1 GYENCAJAGYMHGR-UHFFFAOYSA-N 0.000 description 1
- VLILMVBZOGKIMC-UHFFFAOYSA-N [3-[(1-hydroxy-3h-2,1-benzoxaborol-6-yl)oxy]phenyl]methanamine Chemical compound NCC1=CC=CC(OC=2C=C3B(O)OCC3=CC=2)=C1 VLILMVBZOGKIMC-UHFFFAOYSA-N 0.000 description 1
- XLFGSVPPEZNIPQ-UHFFFAOYSA-N [4-[(1-hydroxy-3h-2,1-benzoxaborol-6-yl)oxy]phenyl]methanamine Chemical compound C1=CC(CN)=CC=C1OC1=CC=C(COB2O)C2=C1 XLFGSVPPEZNIPQ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001099 anti-trypanosomal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 210000001031 ethmoid bone Anatomy 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000011499 joint compound Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- LCAUVFVOLNRVKG-UHFFFAOYSA-N methyl 5-fluoro-2-nitrobenzoate Chemical compound COC(=O)C1=CC(F)=CC=C1[N+]([O-])=O LCAUVFVOLNRVKG-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007557 neuronal destruction Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LFQDNHWZDQTITF-UHFFFAOYSA-N tavaborole Chemical compound FC1=CC=C2B(O)OCC2=C1 LFQDNHWZDQTITF-UHFFFAOYSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
Definitions
- the invention relates to the field of medical science, specifically to medicinal preparations containing boron compounds as organic active ingredients and their use as antiparasitic agents against protozoa.
- Naegleria fowleri is an amphizoic amoeba-flagellate of the genus Naegleria that can be found in warm fresh water, soil, and mud around the world. While it primarily feeds on bacteria, N. fowleri can—as the only species of genus Naegleria —infect people causing so-called primary amoebic meningoencephalitis (PAM). Human infection usually occurs when water containing N. fowleri is splashed or inhaled into the nasal cavity, for example during recreational water activities or a ritual sinus flush. PAM cases caused by an inhalation of N. fowleri cysts are described as well. Once the trophozoite stage of N.
- PAM primary amoebic meningoencephalitis
- fowleri reaches the nasal cavity, it attaches to the nasal mucosa and then migrates along the olfactory nerve through the cribriform plate to the olfactory bulbs in the central nervous system (CNS).
- CNS central nervous system
- N. fowleri causes severe neuronal destruction leading to cerebral hemorrhage, necrosis, inflammation, and increased intracranial pressure, ultimately leading to death.
- PAM progression is rapid with death usually occurring within 3–7 days after the first symptoms, which are indistinguishable from those caused by a viral or bacterial meningoencephalitis, such as fever, headache, neck stiffness, nausea, seizures, and photophobia. Due to the rapid manifestation of the disease, early and correct diagnosis and timely and effective treatment are essential for the survival of infected patients.
- computed tomography and magnetic resonance imaging can detect various CNS changes, such as diffuse cerebral edema, effusion in the cortical sulcus, and hydrocephalic herniation, or later necrotic areas, stenoses, and aneurysms.
- CNS changes such as diffuse cerebral edema, effusion in the cortical sulcus, and hydrocephalic herniation, or later necrotic areas, stenoses, and aneurysms.
- the presence of N. fowleri can be detected in the patient’s cerebrospinal fluid by various diagnostic methods, such as microbiological culture combined with microscopy and Gram and Wright-Giemsa staining, flow cytometry, immunofluorescence staining, enzyme-linked immunosorbent assay, or diagnostic polymerase chain reaction (PCR).
- PCR diagnostic polymerase chain reaction
- Benzoxaboroles are a class of organic compounds containing boron-heterocyclic scaffolds with pharmacological activities known from prior art.
- document US8461336 describes a use of various aminomethylphenoxy-benzoxaboroles for treatment of inflammatory conditions and Zhang, N., Zoltner, M., Leung, K.-F., Scullion, P., Hutchinson, S., del Pino, R.C., et al. Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles.
- PLoS Pathog .
- Goal of the presented invention is to provide substances with an efficient pharmaceutical activity against N. fowleri that can be used for a treatment of PAM and other amoeba-caused diseases, thereby overcoming the shortcomings of prior art.
- Subject of the presented invention is a use of compounds with activity against Naegleria fowleri characterized by general formula I, wherein: R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from a group comprising -H (or -F as a common pharmacological replacement for hydrogen), aminomethyl group, formyl group, and aminomethyl group carrying a protecting group, and their pharmaceutically acceptable salts and hydrates for treatment of diseases caused by N. fowleri .
- the graph depicts survival curves for experimental PAM treatment in a mouse infection model using compound IIa.
- the graph contains a control group (A), group of untreated mice (B), group of mice treated for 5 days (C), and group of mice treated for 10 days (D).
- Example 1 describes synthesis of compound IIa.
- reaction mixture is then cooled to approximately 40 °C and filtered through sintered glass and the filtrate is diluted with aqueous hydrochloric acid (36 %, 30 mL) and stirred additional 20 hours at 70 °C.
- the mixture is then cooled to room temperature (RT), diluted with brine (200 mL), and extracted with ethyl acetate (5 x 200 mL). Combined organic layers are dried over magnesium sulphate, filtered, and concentrated under vacuum.
- NaBH 4 (162 mg, 4.3 mmol) is added in two portions to a cold (4°C) solution of 4-(3-formyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzonitrile (150 mg, 0.43 mmol) in methanol (3 mL). Reaction is allowed to reach RT and hydrochloric acid (5 mL, 36 %) is added dropwise. Acidified mixture is then stirred for 17 hours at RT.
- Example 2 describes synthesis of compound IId.
- Propargylbromide (50 ⁇ L, 80 % toluene solution) is added to a solution of 5-(4-(aminomethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (50 mg, 0.20 mmol) in N,N -dimethylformamide (1 mL). The reaction mixture is stirred for 16 hours at 40 °C, then diluted with toluene (5 mL) and concentrated under vacuum to distill off the N,N -dimethylformamide.
- Example 3 describes synthesis of compound III.
- Example 4 describes synthesis of compound IV.
- NaBH 4 (95 mg, 2.55 mmol) is added in two portions to a cold (4 °C) solution of 4-(3-(1,3-dioxolan-2-yl)phenoxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (200 mg, 0.51 mmol) in methanol (3 mL). Reaction is allowed to reach RT and hydrochloric acid (5 mL, 36 %) is added dropwise. Acidified mixture is then stirred for 16 hours at 50 °C.
- Example 5 describes synthesis of compound V.
- NaNO 2 (180 mg, 2.6 mmol) is added into a suspension of (5-(3-(1,3-dioxolan-2-yl)phenoxy)-2-aminophenyl)methanol (150 mg, 0.52 mmol) in water (0.5 mL).
- Hydrobromic acid (48 %, 2 mL) is added dropwise over 30 minutes period to the resulting suspension.
- CuBr 2 (582 mg, 2.6 mmol) is added to the intermediary solution of diazonium salt and mixture is heated to 60 °C for 6 hours. Reaction mixture is diluted with cold water (5mL) and extracted with ethyl acetate (5 x 10 mL) and combined organic layers are dried over magnesium sulphate.
- the resulting powdery solid is purified by column chromatography (CHCl 3 /CH 3 OH/NH 3 100:1:0.1 ⁇ 10:1:0.1) to yield 5-(3-(aminomethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (13 mg, 62 % yield).
- Example 6 describes culturing of N. fowleri .
- Naegleria fowleri strain HB-1 is cultured under aerobic condition in 2 % animal-origin pancreatic enzymatic digest of casein supplemented with 10 % heat-inactivated fetal bovine serum and with the addition of penicillin (100 U/mL) and streptomycin (100 ⁇ g/mL).
- Cells are cultivated in a 25 cm 2 cultivation flasks under aerobic conditions at 37 °C. To maintain the exponential growth, the culture is 100x diluted and transferred to a new cultivation flask every 3 days.
- Example 7 describes drug-potency testing for growth-inhibition of N. fowleri with different benzoxaboroles.
- the culture medium is supplemented with 10 nM purified human MAO-B.
- Cell viability is determined after 72 h of exposure using a luminescent cell viability assay and the luminescent signal is read in a plate reader and the resulting data are analyzed.
- Example 8 describes results of dose–response analysis for growth-inhibition of N. fowleri with different benzoxaboroles.
- Example 9 describes testing of activity of compound IIa in a murine model.
- a group of 14 BALB/c mice, 12 weeks old and weighing 20 g, are intranasally infected with 2x104 cells of N. fowleri in phosphate-buffered saline (PBS) in a total volume of 30 ⁇ L under diethyl ether anesthesia.
- PBS phosphate-buffered saline
- To obtain virulent N. fowleri cells they are passaged through mice and each time, the brain is extracted postmortem, washed in a growth medium, and parasites are cultured in a cultivation flask at 37 °C. This procedure is repeated at least three times before experimental treatment.
- the experimental treatment of PAM begins 24 h after intranasal infection by N. fowleri cells.
- 50 mg/kg of compound IIa in PBS in a total volume of 200 ⁇ L is administered intraperitoneally in a group of 7 mice every 8 hours for 5 or 10 days.
- the untreated control group containing 7 infected mice is treated in parallel with 200 ⁇ l PBS omitting the drug.
- Three uninfected mice are given the same IIa doses as the treated group as a toxicity control.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compounds based on benzoxaborole moiety with activity against parasitic amoeba of genus Naegleria can be used in treatment of diseases caused by such parasites. Activity of the compounds against Naegleria fowleri was proven by a phenotypic screening approach, which detected potent activity of aminomethylphenoxy-benzoxaboroles with nanomolar or low-micromolar potency depending on the position of the aminomethyl substitution. Potential of the compounds to be used for treatment of primary amoebic meningoencephalitis was demonstrated and proven in murine model infected with N. fowleri. Further, activity of compounds carrying a formyl group as direct metabolites of aminomethyl-derivatives as well as activity of prodrugs with a protecting group attached to the amino group that is cleavable under physiological conditions was also shown.
Description
The invention relates to the field of medical science, specifically to medicinal preparations containing boron compounds as organic active ingredients and their use as antiparasitic agents against protozoa.
Naegleria fowleri is an amphizoic amoeba-flagellate of the genus Naegleria that can be found in warm fresh water, soil, and mud around the world. While it primarily feeds on bacteria, N. fowleri can—as the only species of genus Naegleria—infect people causing so-called primary amoebic meningoencephalitis (PAM). Human infection usually occurs when water containing N. fowleri is splashed or inhaled into the nasal cavity, for example during recreational water activities or a ritual sinus flush. PAM cases caused by an inhalation of N. fowleri cysts are described as well. Once the trophozoite stage of N. fowleri reaches the nasal cavity, it attaches to the nasal mucosa and then migrates along the olfactory nerve through the cribriform plate to the olfactory bulbs in the central nervous system (CNS). There, N. fowleri causes severe neuronal destruction leading to cerebral hemorrhage, necrosis, inflammation, and increased intracranial pressure, ultimately leading to death. PAM progression is rapid with death usually occurring within 3–7 days after the first symptoms, which are indistinguishable from those caused by a viral or bacterial meningoencephalitis, such as fever, headache, neck stiffness, nausea, seizures, and photophobia. Due to the rapid manifestation of the disease, early and correct diagnosis and timely and effective treatment are essential for the survival of infected patients. At the onset of the disease, computed tomography and magnetic resonance imaging can detect various CNS changes, such as diffuse cerebral edema, effusion in the cortical sulcus, and hydrocephalic herniation, or later necrotic areas, stenoses, and aneurysms. The presence of N. fowleri can be detected in the patient’s cerebrospinal fluid by various diagnostic methods, such as microbiological culture combined with microscopy and Gram and Wright-Giemsa staining, flow cytometry, immunofluorescence staining, enzyme-linked immunosorbent assay, or diagnostic polymerase chain reaction (PCR).
Due to its fast progression, PAM has an extremely high mortality rate and most cases of PAM are diagnosed only post-mortem. From 1935 to 2019, 381 cases of PAM have been reported worldwide with only 7 survivors. In these individuals, recovery was achieved by an administration of amphotericin B, either intravenously or intrathecally, alone or in a combination with other drugs such as fluconazole, miconazole, azithromycin, rifampin, or miltefosine. However, there is currently no efficient treatment for PAM available and no known pharmaceutically active substances with a significant activity against N. fowleri. The selection of a drug candidate is further complicated by the cerebral localization of N. fowleri. Thus, an effective drug must not only have a rapid and potent effect, but also the crucial ability to efficiently cross the blood–brain barrier.
Benzoxaboroles are a class of organic compounds containing boron-heterocyclic scaffolds with pharmacological activities known from prior art. For example, document US8461336 describes a use of various aminomethylphenoxy-benzoxaboroles for treatment of inflammatory conditions and Zhang, N., Zoltner, M., Leung, K.-F., Scullion, P., Hutchinson, S., del Pino, R.C., et al. Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. PLoS Pathog. 2018, 14(2): e1006850 shows their activity against Trypanosoma brucei; document US10105377 describes a use of 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole as an antifungal agent; documents US9440994, US10301329, WO2014121124, and WO2011019616 describe a use of benzoxaboroles carrying an amide moiety as antiprotozoals; document WO2020123881 describes antiprotozoal activity of benzoxaboroles carrying carbamate group and its various thio-analogues; document WO2019108982 describes antiprotozoal activity of benzoxaboroles carrying structurally variying substituents with a low molecular weight; document US10011616 describes a use of benzoxaboroles carrying pyrazinoxy substituents as antiprotozoals; document US9346834 describes a use of benzoxaboroles carrying alkoxy substituents as antiprotozoals; document WO2011022337 describes antiprotozoal activity of benzoxaboroles substituted with an alkyl chain carrying a carboxyl or an ester group; and document WO2011019612 describes a use of benzoxaboroles carrying carbamide or thiocarbamide groups as antiprotozoals. However, none of these documents mention a specific activity of benzoxaboroles against N. fowleri or any other amoeba.
Goal of the presented invention is to provide substances with an efficient pharmaceutical activity against N. fowleri that can be used for a treatment of PAM and other amoeba-caused diseases, thereby overcoming the shortcomings of prior art.
Subject of the presented invention is a use of compounds with activity against Naegleria fowleri characterized by general formula I,
wherein:
R1, R2, R3, R4, and R5 are independently selected from a group comprising -H (or -F as a common pharmacological replacement for hydrogen), aminomethyl group, formyl group, and aminomethyl group carrying a protecting group,
and their pharmaceutically acceptable salts and hydrates for treatment of diseases caused by N. fowleri.
wherein:
R1, R2, R3, R4, and R5 are independently selected from a group comprising -H (or -F as a common pharmacological replacement for hydrogen), aminomethyl group, formyl group, and aminomethyl group carrying a protecting group,
and their pharmaceutically acceptable salts and hydrates for treatment of diseases caused by N. fowleri.
Activity of compounds of general formula I against N. fowleri was demonstrated by a phenotypic screening approach, which detected potent activity of aminomethylphenoxy-benzoxaboroles with nanomolar or low-micromolar potency depending on the position of the aminomethyl substitution with compound of formula IIa showing the highest potency with a half-maximal effective concentration (EC50) of 150 nM. Therefore, this compound was selected for an assessment in a murine infection model.
Further, activity of compounds carrying a formyl group as direct metabolites of aminomethyl-derivatives was proven using bovine serum with inherent amine oxidase present in the phenotypic screening as well as in in vivo experiments. Consistently, the aldehyde metabolite IIb has a similar potency as IIa when applied directly. On the other hand, the respective carboxylic derivative IIc has no significant activity against N. fowleri.
Potential use of compounds of formula I in a form of prodrugs with a protecting group that is cleavable under physiological conditions attached to the amino group was also demonstrated. Compound of formula IId carrying a propargyl protecting group showed activity comparable to compound IIa in the presence of 10 nM of human monoamine oxidase B (MAO-B) enzyme, which is abundant in brain tissue.
Example 1 describes synthesis of compound IIa.
4-fluorobenzonitrile (1.48 g 12.24 mmol) and benzo[c][1,2]oxaborole-1,6(3H)-diol (1.0 g, 4.08 mmol) are added to a suspension of Cs2CO3 (13.29 g, 40.80 mmol) and K2CO3 (5.64g, 40.8 mmol) in N,N-dimethylformamide (30mL). The resulting slurry is heated to 100 °C and stirred for 16 hours. The reaction mixture is then cooled to approximately 40 °C and filtered through sintered glass and the filtrate is diluted with aqueous hydrochloric acid (36 %, 30 mL) and stirred additional 20 hours at 70 °C. The mixture is then cooled to room temperature (RT), diluted with brine (200 mL), and extracted with ethyl acetate (5 x 200 mL). Combined organic layers are dried over magnesium sulphate, filtered, and concentrated under vacuum. A silica column chromatography (CHCl3/CH3OH 100:1 → 10:1) yields two products: 4-(4-bromo-3-formylphenoxy)benzonitrile (368 mg, 30 % yield) and 4-(4-bromo-3-formylphenoxy)benzoic acid (326 mg, 25 % yield).
1H NMR: δ 7.00-7.19 (3H, 7.06 (ddd, J = 8.3, 1.3, 0.5 Hz), 7.13 (dd, J = 8.2, 1.4 Hz)), 7.29 (1H, dd, J = 8.2, 0.5 Hz), 7.68 (1H, dd, J = 1.4, 0.5 Hz), 8.10 (2H, ddd, J = 8.3, 1.9, 0.5 Hz), 10.03 (1H, s).
MS Calculated for C14H9BrNO2 +: 301.98112, Found: 301.95823
1H NMR: δ 7.04-7.20 (3H, 7.11 (ddd, J = 8.5, 1.4, 0.4 Hz), 7.14 (dd, J = 8.2, 1.4 Hz)), 7.29 (1H, dd, J = 8.2, 0.5 Hz), 7.68 (1H, dd, J = 1.4, 0.5 Hz), 7.93 (2H, ddd, J = 8.5, 1.4, 0.4 Hz), 10.03 (1H, s).
MS Calculated for C14H8BrO4 -: 318.96114, Found: 318.97423
In the next stage, 4-(4-bromo-3-formylphenoxy)benzonitrile (0.2 g, 0.66 mmol) is added to a flask charged with bis(pinacolato)diboran (335 mg, 1.3 mmol), PdCl2(dppf) (24 mg, 0.033 mmol), CH3COOK (130 mg, 1.3 mmol). Anhydrous 1,4-dioxan (4 mL) is added to all the solids and the resulting cloudy suspension is stirred for 3 hours while heated to 100 °C under argon atmosphere. TLC (thin-layer chromatography) (CHCl3/CH3OH/NH3 100:2:0.2) indicates consumption of the starting material. The mixture is concentrated under vacuum and subjected to column chromatography (CHCl3/CH3OH 100:2). Combined chromatographic fractions yields 4-(3-formyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzonitrile (209 mg, 91 % yield).
1H NMR: δ 1.35 (12H, s), 7.00-7.20 (3H, 7.07 (ddd, J = 8.6, 1.4, 0.5 Hz), 7.13 (dd, J = 8.4, 1.4 Hz)), 7.29 (1H, dd, J = 8.4, 0.5 Hz), 7.60 (1H, dd, J = 1.4, 0.5 Hz), 8.08 (2H, ddd, J = 8.6, 1.9, 0.5 Hz), 10.07 (1H, s).
MS Calculated for C20H21BNO4 +: 350.15582, Found: 350.16212
In the next stage, NaBH4 (162 mg, 4.3 mmol) is added in two portions to a cold (4°C) solution of 4-(3-formyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzonitrile (150 mg, 0.43 mmol) in methanol (3 mL). Reaction is allowed to reach RT and hydrochloric acid (5 mL, 36 %) is added dropwise. Acidified mixture is then stirred for 17 hours at RT. Mixture is concentrated under vacuum and the residuum is purified by column chromatography (CHCl3/CH3OH 100:1 → 100:5) to yield 4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile (93 mg, 86 % yield).
1H NMR: δ 4.77 (2H, d, J = 14.3 Hz), 6.53 (1H, dd, J = 2.4, 0.5 Hz), 6.99-7.13 (3H, 7.06 (dd, J = 8.1, 2.4 Hz), 7.06 (ddd, J = 8.6, 1.4, 0.5 Hz)), 7.35 (1H, dd, J = 8.1, 0.5 Hz), 8.09 (2H, ddd, J = 8.6, 1.9, 0.5 Hz).
MS Calculated for C14H11BNO3 +: 252.08265, Found: 252.09172
In the next stage, ethanol (6 mL) is added to a flask charged with Pd/C (10 %, 30 mg) and 4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile (100 mg, 0.40 mmol). Reaction vessel is submitted to H2/vacuum cycle (4x) to remove residual oxygen. After the last cycle, the reaction is stirred (16 hours) under H2 atmosphere. After TLC (CHCl3/CH3OH/NH3 10:1:0.1) indicates a consumption of the starting material, the mixture is filtered through a pad of celite and concentrated under vacuum. Column chromatography (CHCl3/CH3OH/NH3 100:10:0.1 → 10:1:0.1) of crude product yields 5-(4-(aminomethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (80 mg, 79 % yield).
1H NMR: δ 3.68 (2H, s), 4.77 (2H, d, J = 14.3 Hz), 6.61 (1H, dd, J = 2.4, 0.5 Hz), 6.92 (2H, ddd, J = 8.2, 1.3, 0.5 Hz), 7.15-7.41 (4H, 7.21 (dd, J = 8.1, 2.4 Hz), 7.23 (ddd, J = 8.2, 1.3, 0.5 Hz), 7.34 (dd, J = 8.1, 0.5 Hz).
MS Calculated for C14H15BNO3 +: 256.11395, Found: 256.12547
Example 2 describes synthesis of compound IId.
Propargylbromide (50 µL, 80 % toluene solution) is added to a solution of 5-(4-(aminomethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (50 mg, 0.20 mmol) in N,N-dimethylformamide (1 mL). The reaction mixture is stirred for 16 hours at 40 °C, then diluted with toluene (5 mL) and concentrated under vacuum to distill off the N,N-dimethylformamide. The crude product is purified with column chromatography (CHCl3/CH3OH/NH3 100:10:0.1 → 10:1:0.1) to yield 5-(4-((prop-2-yn-1-ylamino)methyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (12 mg, 21 % yield).
1H NMR: δ 2.80 (1H, s), 3.06 (2H, s), 3.59 (2H, s), 4.77 (2H, d, J = 14.3 Hz), 6.61 (1H, dd, J = 2.4, 0.5 Hz), 6.92 (2H, ddd, J = 8.2, 1.3, 0.5 Hz), 7.21 (1H, dd, J = 8.1, 2.4 Hz), 7.28-7.41 (3H, 7.34 (dd, J = 8.1, 0.5 Hz), 7.35 (ddd, J = 8.2, 1.2, 0.5 Hz).
MS Calculated for C17H17BNO3 +: 294.12960, Found: 294.12235
MS Calculated for C17H17BNO3 +: 294.12960, Found: 294.12235
Example 3 describes synthesis of compound III.
4-Fluorobenzonitrile (726 mg, 6 mmol) and benzo[c][1,2]oxaborole-1,6(3H)-diol (300 mg, 2 mmol) are added to a suspension of Cs2CO3 (6.52 g, 20 mmol) and K2CO3 (2.76 g, 20 mmol) in N,N-dimethylformamide (10 mL). The resulting slurry is heated to 95 °C and stirred for 19 hours. The reaction mixture is then cooled to RT, diluted with ethanol (10 mL), and filtered. Filtrate is acidified with hydrochloride acid (5 mL, 36 %) and stirred for 12 hours at RT. The solution is concentrated under vacuum and crude product is purified on silica by column chromatography (CHCl3/CH3OH/NH3 100:1 → 10:1) to yield 4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)benzonitrile (142 mg, 33 % yield).
1H NMR: δ 4.74 (2H, d, J = 13.8 Hz), 7.00-7.20 (3H, 7.06 (ddd, J = 8.3, 1.3, 0.5 Hz), 7.13 (dd, J = 8.4, 2.7 Hz)), 7.26 (1H, dd, J = 8.4, 0.5 Hz), 7.42 (1H, dd, J = 2.7, 0.5 Hz), 8.09 (2H, ddd, J = 8.3, 1.9, 0.5 Hz).
MS Calculated for C14H11BNO3 +: 252.08265, Found: 252.07985
In the next stage, ethanol (4 mL) is added to a flask charged with Pd/C (10 %, 25 mg) and dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)benzonitrile (100 mg, 0.4 mmol). Reaction vessel is submitted to H2/vacuum cycle (4x) to remove residual oxygen. After the last cycle, the reaction is stirred for 16 hours under H2 atmosphere. After TLC (CHCl3/CH3OH/NH3 10:1:0.1) indicates consumption of the starting material, the mixture is filtered through a pad of celite and concentrated under vacuum. Column chromatography (CHCl3/CH3OH/NH3 100:10:0.1 → 10:1:0.1) of crude product yields 6-(4-(aminomethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (84 mg, 83 % yield).
1H NMR: δ 3.70 (2H, s), 4.76 (2H, d, J = 13.8 Hz), 6.86-7.11 (3H, 6.92 (ddd, J = 8.2, 1.5, 0.5 Hz), 7.05 (dd, J = 8.5, 2.8 Hz)), 7.16-7.31 (3H, 7.23 (ddd, J = 8.2, 1.3, 0.5 Hz), 7.25 (dd, J = 8.5, 0.5 Hz)), 7.40 (1H, dd, J = 2.8, 0.5 Hz).
MS Calculated for C14H15BNO3 +: 256.11395, Found: 256.12359
Example 4 describes synthesis of compound IV.
3-(1,3-Dioxolan-2-yl)phenol (1.23g, 7.39 mmol) and 2-bromo-4-fluorobenzaldehyde (1.0 g, 4.92 mmol) are added to a suspension of Cs2CO3 (8.0 g, 24.6 mmol) and K2CO3 (3.4 g, 24.5 mmol) in N,N-dimethylformamide (20 mL). The resulting slurry is heated to 95 °C and stirred for 16 hours. The reaction mixture is then cooled to RT, diluted with ethanol (20 mL), and filtered through glass frit. The column chromatography (CHCl3/CH3OH 100:1 → 100:5) of crude product yields 4-(3-(1,3-dioxolan-2-yl)phenoxy)-2-bromobenzaldehyde (1.15 g, 67 % yield).
1H NMR: δ 3.78-3.99 (4H, 3.86 (ddd, J = 11.6, 5.7, 5.3 Hz), 3.91 (ddd, J = 11.6, 5.6, 5.3 Hz)), 5.44 (1H, s), 6.83-7.21 (4H, 6.89 (dd, J = 8.1, 2.0 Hz), 6.97 (ddd, J = 8.1, 2.8, 1.3 Hz), 7.04 (ddd, J = 8.0, 2.5, 1.3 Hz), 7.15 (ddd, J = 2.8, 2.5, 0.6 Hz)), 7.39 (1H, ddd, J = 8.1, 8.0, 0.6 Hz), 7.52 (1H, dd, J = 2.0, 0.5 Hz), 8.10 (1H, dd, J = 8.1, 0.5 Hz), 9.99 (1H, s).
MS Calculated for C16H14BrO4 +: 349.00700, Found: 349.01256
In the next stage, 4-(3-(1,3-dioxolan-2-yl)phenoxy)-2-bromobenzaldehyde (0.5 g, 1.26 mmol) is added into a flask charged with bis(pinacolato)diboran (639 mg, 2.52 mmol), PdCl2(dppf) (46 mg, 0.06 mmol), and CH3COOK (247 mg, 2.52 mmol). Anhydrous 1,4-dioxan (10 mL) is added to all the solids and the cloudy suspension is stirred for 3 hours while heated to 100 °C under argon atmosphere. TLC (CHCl3/CH3OH/NH3 100:2:0.2) indicates consumption of the starting material. The mixture is concentrated under vacuum and subjected to column chromatography (CHCl3/CH3OH 100:2). Combined chromatographic fractions yield 4-(3-(1,3-dioxolan-2-yl)phenoxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (404 mg, 81 % yield).
1H NMR: δ 1.36 (12H, s), 3.78-3.99 (4H, 3.86 (ddd, J = 11.6, 5.7, 5.3 Hz), 3.91 (ddd, J = 11.6, 5.6, 5.3 Hz)), 5.44 (1H, s), 6.84-7.21 (4H, 6.91 (dd, J = 7.9, 2.0 Hz), 6.97 (ddd, J = 8.1, 2.8, 1.3 Hz), 7.03 (ddd, J = 8.0, 2.6, 1.3 Hz), 7.15 (ddd, J = 2.8, 2.6, 0.6 Hz)), 7.32-7.55 (2H, 7.39 (ddd, J = 8.1, 8.0, 0.6 Hz), 7.50 (dd, J = 2.0, 0.5 Hz)), 7.73 (1H, dd, J = 7.9, 0.5 Hz), 10.04 (1H, s).
MS Calculated for C22H26BO6 +: 397.18170, Found: 397.18257
In the next stage, NaBH4 (95 mg, 2.55 mmol) is added in two portions to a cold (4 °C) solution of 4-(3-(1,3-dioxolan-2-yl)phenoxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (200 mg, 0.51 mmol) in methanol (3 mL). Reaction is allowed to reach RT and hydrochloric acid (5 mL, 36 %) is added dropwise. Acidified mixture is then stirred for 16 hours at 50 °C. Mixture is concentrated under vacuum and the residuum is purified by column chromatography (CHCl3/CH3OH 100:1 → 100:5) to yield 3-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)-benzaldehyde (61 mg, 47 % yield).
1H NMR: δ 4.76 (2H, d, J = 13.8 Hz), 6.92-7.11 (2H, 6.98 (dt, J = 8.2, 1.4 Hz), 7.05 (dd, J = 8.5, 2.8 Hz)), 7.25 (1H, dd, J = 8.5, 0.5 Hz), 7.35-7.53 (2H, 7.40 (dd, J = 2.8, 0.5 Hz), 7.46 (ddd, J = 8.3, 8.2, 0.4 Hz)), 7.68 (1H, ddd, J = 1.7, 1.4, 0.4 Hz), 7.93 (1H, ddd, J = 8.3, 1.7, 1.4 Hz), 10.00 (1H, s).
MS Calculated for C14H12BO4 +: 255.08232, Found: 255.09120
In the next stage, NH4
+HCCO- (186 mg, 2.95mmol) and NaBH3CN (120 mg, 1.9 mmol) are added in one portion to a solution of 3-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)benzaldehyde (50 mg, 0.19 mmol) in methanol (3 mL). The resulting mixture is stirred for 14 hours at RT, concentrated under vacuum and subjected to column chromatography (CHCl3/CH3OH/NH3 100:1:0.1 → 10:1:0.1). The combined fractions yield 6-(3-(aminomethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (37 mg, 77 % yield).
1H NMR: δ 3.78 (2H, s), 4.76 (2H, d, J = 13.8 Hz), 6.86-7.33 (6H, 6.92 (ddd, J = 8.2, 2.8, 1.4 Hz), 7.02 (ddd, J = 2.8, 2.6, 0.5 Hz), 7.05 (dd, J = 8.5, 2.8 Hz), 7.13 (ddd, J = 7.9, 2.6, 1.4 Hz), 7.25 (ddd, J = 8.2, 7.9, 0.5 Hz), 7.25 (dd, J = 8.5, 0.5 Hz)), 7.40 (1H, dd, J = 2.8, 0.5 Hz).
MS Calculated for C14H15BNO3 +: 256.11395, Found: 256.11268
Example 5 describes synthesis of compound V.
3-(1,3-Dioxolan-2-yl)phenol (1 g, 6 mmol) and methyl 5-fluoro-2-nitrobenzoate (1.198 g, 6 mmol) are added into a flask charged with Cs2CO3 (9.77 g, 30 mmol), K2CO3 (4.16 g, 30 mmol), and N,N-dimethylformamide (20 mL). Reaction mixture is sonicated for 120 minutes, then stirred for 24 hours and heated to 90 °C. Reaction mixture is then washed with ethyl-acetate (3 x 500 mL) and brine (250 mL). Combined organic layer is dried over magnesium sulfate and concentrated under vacuum. Crude product is purified by column chromatography (petroleum ether/ethy acetate 10:1→2:1) to yield methyl 5-(3-(1,3-dioxolan-2-yl)phenoxy)-2-nitrobenzoate (1.12 g, 54 % yield).
1H NMR: δ 3.65 (3H, s), 3.78-3.99 (4H, 3.86 (ddd, J = 11.6, 5.7, 5.3 Hz), 3.91 (ddd, J = 11.6, 5.6, 5.3 Hz)), 5.45 (1H, s), 6.92-7.22 (3H, 6.99 (ddd, J = 8.1, 2.8, 1.3 Hz), 7.04 (ddd, J = 8.0, 2.5, 1.3 Hz), 7.16 (ddd, J = 2.8, 2.5, 0.6 Hz)), 7.36-7.57 (2H, 7.43 (ddd, J = 8.1, 8.0, 0.6 Hz), 7.51 (dd, J = 8.6, 1.5 Hz)), 7.99 (1H, dd, J = 1.5, 0.5 Hz), 8.13 (1H, dd, J = 8.6, 0.5 Hz).
MS Calculated for C17H16NO7 +: 346.09213, Found: 346.08920
In the next stage, LiAlH4 (5 mL, 2 M in tetrahydrofuran (THF)) is added to a solution of methyl 5-(3-(1,3-dioxolan-2-yl)phenoxy)-2-nitrobenzoate (350 mg, 1 mmol) in anhydrous tetrahydrofurane (5 mL). After 4 hours of stirring at RT, the reaction is quenched by addition of silica (5 g) and filtered through sintered glass. The filtrate is diluted with acetone (5 mL) and concentrated under vacuum and the crude product is purified by column chromatography (CHCl3/CH3OH/NH3 100:1:0.1 → 10:1:0.1) to yield (5-(3-(1,3-dioxolan-2-yl)phenoxy)-2-aminophenyl)methanol (183 mg, 64 % yield).
1H NMR: δ 3.78-3.99 (4H, 3.86 (ddd, J = 11.6, 5.7, 5.3 Hz), 3.91 (ddd, J = 11.6, 5.6, 5.3 Hz)), 4.48 (2H, s), 5.46 (1H, s), 6.44 (1H, dd, J = 8.4, 0.5 Hz), 6.64-6.86 (2H, 6.70 (dd, J = 2.8, 0.5 Hz), 6.80 (dd, J = 8.4, 2.8 Hz)), 6.86-7.18 (3H, 6.93 (ddd, J = 8.2, 2.8, 1.3 Hz), 7.02 (ddd, J = 8.1, 2.6, 1.3 Hz), 7.13 (ddd, J = 2.8, 2.6, 0.5 Hz)), 7.37 (1H, td, J = 8.1, 0.5 Hz).
MS Calculated for C16H18NO4 +: 288.12303, Found: 288.11923
In the next stage, NaNO2 (180 mg, 2.6 mmol) is added into a suspension of (5-(3-(1,3-dioxolan-2-yl)phenoxy)-2-aminophenyl)methanol (150 mg, 0.52 mmol) in water (0.5 mL). Hydrobromic acid (48 %, 2 mL) is added dropwise over 30 minutes period to the resulting suspension. CuBr2 (582 mg, 2.6 mmol) is added to the intermediary solution of diazonium salt and mixture is heated to 60 °C for 6 hours. Reaction mixture is diluted with cold water (5mL) and extracted with ethyl acetate (5 x 10 mL) and combined organic layers are dried over magnesium sulphate. Magnesium sulphate is filtered, filtrate is concentrated under vacuum, and the crude product is purified by column chromatography (CHCl3/CH3OH/NH3 100:1:0.1 → 10:1:0.1) to yield 3-(4-bromo-3-(hydroxymethyl)phenoxy)benzaldehyde (65 mg, 41 % yield).
1H NMR: δ 4.62 (2H, s), 6.79 (1H, dd, J = 2.9, 0.6 Hz), 6.87-7.04 (2H, 6.93 (dd, J = 8.3, 2.9 Hz), 6.98 (dt, J = 8.2, 1.4 Hz)), 7.32 (1H, dd, J = 8.3, 0.6 Hz), 7.46 (1H, ddd, J = 8.3, 8.2, 0.4 Hz), 7.68 (1H, ddd, J = 1.7, 1.4, 0.4 Hz), 7.93 (1H, ddd, J = 8.3, 1.7, 1.4 Hz), 10.00 (1H, s).
MS Calculated for C14H12BrO3 +: 306.99643, Found: 306.98562
In the next stage, 3-(4-bromo-3-(hydroxymethyl)phenoxy)benzaldehyde (50 mg, 0.16 mmol) is added into a flask charged with bis(pinacolato)diboran (83 mg, 0.32 mmol), PdCl2(dppf) (6 mg, 0.08 mmol), and CH3COOK (32 mg, 0.32 mmol). Anhydrous 1,4-dioxan (2 mL) is added to all the solids and the cloudy suspension is stirred for 1.5 hours while heated to 95 °C under argon atmosphere. TLC (CHCl3/CH3OH/NH3 100:5:0.5) indicates consumption of the starting material. The mixture is concentrated under vacuum and subjected to column chromatography (CHCl3/CH3OH 100:2 → 100:5). Combined chromatographic fractions yield 3-(3-(hydroxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzaldehyde (37 mg, 66 % yield).
1H NMR: δ 1.35 (12H, s), 4.51 (2H, s), 6.51 (1H, dd, J = 2.4, 0.5 Hz), 6.89-7.06 (2H, 6.96 (dd, J = 8.1, 2.4 Hz), 6.99 (dt, J = 8.2, 1.4 Hz)), 7.28-7.54 (2H, 7.34 (dd, J = 8.1, 0.5 Hz), 7.47 (ddd, J = 8.3, 8.2, 0.4 Hz)), 7.70 (1H, td, J = 1.4, 0.4 Hz), 7.94 (1H, dt, J = 8.3, 1.4 Hz), 10.00 (1H, s).
MS Calculated for C20H24BO5 +: 355.17113, Found: 355.16910
In the next stage, NH4
+HCCO- (80 mg, 1.23 mmol) and NaBH3CN (53 mg, 0.85 mmol) are added in one portion to a solution of 3-(3-(hydroxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzaldehyde (30 mg, 0.085 mmol) in methanol (2 mL). The resulting mixture is stirred for 14 hours at RT, reaction is quenched with aqueous hydrochlorid acid (3 mL, 36 %) and stirred for additional 12 hours. The pH of the mixture is adjusted to approximately 7 by addition of NaOH (1M), mixture is frozen to -50°C and freeze-dried. The resulting powdery solid is purified by column chromatography (CHCl3/CH3OH/NH3 100:1:0.1 → 10:1:0.1) to yield 5-(3-(aminomethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol (13 mg, 62 % yield).
1H NMR: δ 3.78 (2H, s), 4.77 (2H, d, J = 14.3 Hz), 6.61 (1H, dd, J = 2.4, 0.5 Hz), 6.87-7.41 (6H, 6.93 (ddd, J = 8.2, 2.8, 1.4 Hz), 7.03 (ddd, J = 2.8, 2.6, 0.5 Hz), 7.14 (ddd, J = 7.9, 2.6, 1.4 Hz), 7.21 (dd, J = 8.1, 2.4 Hz), 7.26 (ddd, J = 8.2, 7.9, 0.5 Hz), 7.35 (dd, J = 8.1, 0.5 Hz).
MS Calculated for C14H15BNO3 +: 256.11395, Found: 256.10985
Example 6 describes culturing of N. fowleri.
Naegleria fowleri strain HB-1 is cultured under aerobic condition in 2 % animal-origin pancreatic enzymatic digest of casein supplemented with 10 % heat-inactivated fetal bovine serum and with the addition of penicillin (100 U/mL) and streptomycin (100 µg/mL). Cells are cultivated in a 25 cm2 cultivation flasks under aerobic conditions at 37 °C. To maintain the exponential growth, the culture is 100x diluted and transferred to a new cultivation flask every 3 days.
Example 7 describes drug-potency testing for growth-inhibition of N. fowleri with different benzoxaboroles.
The EC50is determined by exposing N. fowleri cells to various benzoxaborole-based compounds at different concentrations for 72 hours in 96-well plates (n=3). Each well contains 550 cells in a total volume of 100 µL of culture medium. For in vitro activation of MAO-B-sensitive methylamine prodrug derivatives, the culture medium is supplemented with 10 nM purified human MAO-B. Cell viability is determined after 72 h of exposure using a luminescent cell viability assay and the luminescent signal is read in a plate reader and the resulting data are analyzed.
Example 8 describes results of dose–response analysis for growth-inhibition of N. fowleri with different benzoxaboroles.
EC50 = 0.15 µM | |
EC50 = 0.18 µM | |
EC50 > 50 µM | |
EC50=0.16 µM (in the presence of 10 nM MAO-B) | |
EC50 = 2.17 µM | |
EC50 = 0.92 µM | |
EC50 = 1.96 µM |
Example 9 describes testing of activity of compound IIa in a murine model.
A group of 14 BALB/c mice, 12 weeks old and weighing 20 g, are intranasally infected with 2x104 cells of N. fowleri in phosphate-buffered saline (PBS) in a total volume of 30 μL under diethyl ether anesthesia. To obtain virulent N. fowleri cells, they are passaged through mice and each time, the brain is extracted postmortem, washed in a growth medium, and parasites are cultured in a cultivation flask at 37 °C. This procedure is repeated at least three times before experimental treatment.
The experimental treatment of PAM begins 24 h after intranasal infection by N. fowleri cells. 50 mg/kg of compound IIa in PBS in a total volume of 200 μL is administered intraperitoneally in a group of 7 mice every 8 hours for 5 or 10 days. The untreated control group containing 7 infected mice is treated in parallel with 200 μl PBS omitting the drug. Three uninfected mice are given the same IIa doses as the treated group as a toxicity control.
Use of benzoxaborole-based compounds in therapy of diseases caused by amoebas of the Naegleria genus is industrially applicable in the development and production of medicinal products against diseases caused by Naegleria fowleri.
Claims (1)
- Benzoxaborole-based compounds of general formula I,
wherein:
R1, R2, R3, R4, and R5 are independently selected from a group comprising -H, -F, aminomethyl group, formyl group, and aminomethyl group carrying a protecting group,
and their pharmaceutically acceptable salts and hydrates
for use in treatment of diseases caused by Naegleria fowleri.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CZ2022/050116 WO2024094235A1 (en) | 2022-11-03 | 2022-11-03 | Use of benzoxaborole-based compounds in therapy of diseases caused by amoebas of the naegleria genus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CZ2022/050116 WO2024094235A1 (en) | 2022-11-03 | 2022-11-03 | Use of benzoxaborole-based compounds in therapy of diseases caused by amoebas of the naegleria genus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024094235A1 true WO2024094235A1 (en) | 2024-05-10 |
Family
ID=84689118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2022/050116 WO2024094235A1 (en) | 2022-11-03 | 2022-11-03 | Use of benzoxaborole-based compounds in therapy of diseases caused by amoebas of the naegleria genus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024094235A1 (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011019612A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
WO2011019616A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
WO2011022337A1 (en) | 2009-08-19 | 2011-02-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US8461336B2 (en) | 2008-09-04 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2014121124A1 (en) | 2013-02-01 | 2014-08-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US9346834B2 (en) | 2009-10-20 | 2016-05-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US9440994B2 (en) | 2009-08-14 | 2016-09-13 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules as antiprotozoal agents |
US10011616B2 (en) | 2015-04-09 | 2018-07-03 | Mmv Medicines For Malaria Venture | Boron-containing small molecules as antiprotozoal1 agents |
US10105377B2 (en) | 2014-05-05 | 2018-10-23 | Pfizer Inc. | Compounds and nail polish |
WO2019108982A1 (en) | 2017-11-30 | 2019-06-06 | Boragen, Inc. | Benzoxaborole compounds and formulations thereof |
WO2020123881A1 (en) | 2018-12-12 | 2020-06-18 | Boragen, Inc. | Boron containing compounds and their uses |
-
2022
- 2022-11-03 WO PCT/CZ2022/050116 patent/WO2024094235A1/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8461336B2 (en) | 2008-09-04 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2011019612A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
WO2011019616A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US9440994B2 (en) | 2009-08-14 | 2016-09-13 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules as antiprotozoal agents |
US10301329B2 (en) | 2009-08-14 | 2019-05-28 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
WO2011022337A1 (en) | 2009-08-19 | 2011-02-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US9346834B2 (en) | 2009-10-20 | 2016-05-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
WO2014121124A1 (en) | 2013-02-01 | 2014-08-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US10105377B2 (en) | 2014-05-05 | 2018-10-23 | Pfizer Inc. | Compounds and nail polish |
US10011616B2 (en) | 2015-04-09 | 2018-07-03 | Mmv Medicines For Malaria Venture | Boron-containing small molecules as antiprotozoal1 agents |
WO2019108982A1 (en) | 2017-11-30 | 2019-06-06 | Boragen, Inc. | Benzoxaborole compounds and formulations thereof |
WO2020123881A1 (en) | 2018-12-12 | 2020-06-18 | Boragen, Inc. | Boron containing compounds and their uses |
Non-Patent Citations (1)
Title |
---|
ZHANG, N.ZOLTNER, M.LEUNG, K.-F.SCULLION, P.HUTCHINSON, S.DEL PINO, R.C. ET AL.: "Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles", PLOS PATHOG, vol. 14, no. 2, 2018, pages e1006850 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110461846B (en) | Compound capable of inhibiting and degrading Bruton tyrosine protein kinase Btk activity | |
CN109963844B (en) | Compound for inhibiting and degrading tyrosine protein kinase ALK | |
CN113735862A (en) | Nucleoside compound for treating virus infection and application thereof | |
US7101867B2 (en) | Benzofuran derivatives, their production and use | |
KR900001511B1 (en) | Catechol derivatives and preventive and remedial preparation for regressive disorders | |
CN104059039B (en) | There is the fused ring compound of GPR40 function of receptors adjustment effects | |
WO2021213317A1 (en) | Hpk1 inhibitor, preparation method therefor and use thereof | |
CN114555574A (en) | Chroman compounds targeting aldone reductase 1C3 | |
BR112021006710A2 (en) | compounds analogous to iludin, uses thereof and methods for synthesizing them | |
WO2024094235A1 (en) | Use of benzoxaborole-based compounds in therapy of diseases caused by amoebas of the naegleria genus | |
US20150368213A1 (en) | Novel Inhibitors of System Xc- | |
JP2006523206A (en) | Regulation of cell death | |
WO2020173417A1 (en) | Acryloyl-containing nuclear transport regulator and uses thereof | |
WO2011040509A1 (en) | 2,3-dihydro-1h-indene-2-ylurea derivative and pharmaceutical application of same | |
TWI832045B (en) | Antiviral 1,3-di-oxo-indene compounds | |
US20230131830A1 (en) | Pyrimidine compounds and their pharmaceutical uses | |
US20230219894A1 (en) | Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient | |
CN115708410A (en) | Btk targeted degradation compound and anti-tumor application thereof | |
US7179937B2 (en) | Cyclopentenone derivatives for cancer therapy | |
JP3553442B2 (en) | Benzofuran derivatives, their production and use | |
EP1581471B9 (en) | Cyclopentenone derivatives for cancer therapy | |
US8927566B2 (en) | Norepinephrine and selective serotonin receptor blocker and use thereof | |
US20230357148A1 (en) | Indole derivative and application thereof | |
CN117510514A (en) | Lycorine derivative, pharmaceutical composition thereof and application of lycorine derivative in preparation of antiviral drugs | |
JP4364467B2 (en) | Benzofuran derivatives, their production and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22834475 Country of ref document: EP Kind code of ref document: A1 |